Abrogation of ubiquitin/proteasome-dependent turnover of p53 is critical for its activation. UbL-UBA proteins, including human homolog of Rad23 (hHR23) proteins, may regulate proteasomal degradation of substrates such as p53, due to their ability to interact with both ubiquitinated substrates and the proteasome. siRNAmediated depletion of hHR23A or hHR23B in human cell lines accelerated p53 degradation. In contrast, overexpression of hHR23 proteins led to the accumulation of ubiquitinated p53, and purified hHR23 proteins also blocked p53 proteasome degradation in vitro. An hHR23-MDM2 complex was identified, suggesting that MDM2 and hHR23 cooperate in the regulation of p53 proteasome degradation. Consistent with this hypothesis, an MDM2 mutant that demonstrated increased binding in vivo to hHR23A was able to ubiquitinate, but not degrade p53. Moreover, the defective phenotype of this MDM2 mutant was rescued by siRNA knockdown of hHR23A. Our data indicate that MDM2 acts at a step in the p53 degradation pathway after ubiquitination, to counteract hHR23 inhibition of p53 turnover. Moreover, our data suggest the possibility that ubiquitin ligase/UbL-UBA protein complexes, as exemplified by the MDM2/hHR23 complex, may serve a general role in regulating substrate degradation by the proteasome.
Introduction
p53 activity is controlled in large part through regulated proteasome degradation (reviewed in Ashcroft and Vousden, 1999) . Although regulation of p53 ubiquitination by MDM2 and other factors has been intensively studied, the exact mechanism by which p53, and polyubiquitinated substrates in general, are recognized by the proteasome, remains unclear.
The class of proteasome-interacting proteins that contain ubiquitin-like and ubiquitin-associated domains (UbL-UBA proteins), which include the hPLIC 1 and 2 (yeast Dsk2) and hHR23A and B (yeast Rad23) proteins, may regulate substrate recognition by the proteasome. These proteins share conserved UBA domains which recognize polyubiquitin chains, and conserved UbL domains that recognize the proteasome, consistent with their proposed role as receptors for proteasome substrate recognition (Hiyama et al., 1999; Bertolaet et al., 2001; Wilkinson et al., 2001; Elsasser et al., 2002; Funakoshi et al., 2002) . hPLIC and hHR23 proteins have been shown to modulate p53 proteasome turnover, although the mechanism by which UbL-UBA proteins might control physiologic p53 turnover has not been established (Kleijnen et al., 2000; Zhu et al., 2001a; Glockzin et al., 2003) .
Analysis of UbL-UBA functions in other species and with other substrates has not provided any clear picture of the exact role that these proteins play in regulating proteasome degradation. Genetic analysis of Rad23 function in null strains demonstrates that it is required for turnover of certain proteasome substrates when either Rpn10 or Dsk2 is also absent (Lambertson et al., 1999; Rao and Sastry, 2002) . Other studies, however, point to a negative role for Rad23-family proteins in proteasome function. Rad23-family proteins can block extension of ubiquitin chains (Ortolan et al., 2000; Chen et al., 2001) , and hHR23 proteins can block proteasome degradation of certain substrates (Hiyama et al., 1999; Raasi and Pickart, 2003) . MEFs derived from targeted deletion of the mouse orthologs of hHR23 (mHR23A and B) demonstrated defects in xeroderma pigmentosa group-C (XP-C) protein stabilization, consistent with a role for mHR23 proteins in stabilizing specific proteasome substrates (Ng et al., 2003) .
In this study, we report the coordinate involvement of hHR23 and MDM2 in regulating p53 turnover at the level of the proteasome. Depletion of hHR23A or B with siRNA resulted in more rapid degradation of p53 by the proteasome, while their overexpression led to the accumulation of ubiquitinated p53, and hHR23A and B also blocked in vitro degradation of p53 by the proteasome. A novel hHR23A/MDM2 complex was identified and the ability of hHR23A derivatives to interact with MDM2 in vivo correlated with their ability to stabilize ubiquitinated p53 forms and block in vitro p53 degradation. Further supporting a role for MDM2/ hHR23 complexes in regulating p53 turnover, an MDM2 mutant that demonstrated increased binding to hHR23A, ubiquitinated but did not degrade p53, and its p53 degradation function was restored in cells depleted of hHR23A.
Results

Overexpression of hHR23A causes accumulation of ubiquitinated p53
To investigate the potential involvement of hHR23 proteins in p53 stability regulation, hHR23A-FL (fulllength, residues 1-363) or the truncated hHR23A-Nt (residues 1-154) and hHR23A-Ct (residues 154-363) derivatives ( Figure 1a ) were expressed in U2OS (Figure 1b ) or H1299 cells cotransfected with p53 and MDM2 expression plasmids. Transfection of MDM2 decreased the level of p53 (Figure 1b , compare lanes 3 and 4), reflecting its ability to ubiquitinate and degrade p53 (Haupt et al., 1997; Kubbutat et al., 1997) . Overexpression of hHR23A-FL and hHR23A-Ct resulted in increased levels of slower migrating forms of p53 ( Figure 1b, top panel) . Overexpression of hHR23B, or a truncated derivative lacking its N-terminal 182 residues, also led to increased levels of the same modified p53 forms in U2OS cells, and similar results with hHR23A overexpression were observed in H1299 cells (data not shown).
Transfection of myc-tagged ubiquitin along with p53, MDM2, and hHR23A, followed by anti-myc immunoprecipitation (IP) and p53 immunoblot, allowed identification of modified p53 forms induced by hHR23A or hHR23A-Ct, but not hHR23A-Nt, as ubiquitin conjugates ( Figure 1c ). Similar ubiquitinated species were observed when MDM2 and p53-transfected cells were treated with proteasome inhibitor (Figure 1c) . Thus, overexpression of hHR23A, and sequences within its C-terminus, which include the UBA ubiquitin-binding modules, can increase the abundance of p53-ubiquitin conjugates, likely by blocking their proteasome degradation.
Knockdown of hHR23 proteins decreases p53 abundance and stability
Since overexpression of hHR23 proteins appeared to stabilize or otherwise protect ubiquitinated p53, we investigated the consequences of siRNA-mediated knockdown of endogenous hHR23. In U2OS cells treated with two different hHR23A-specific but not Figure 1 hHR23A overexpression increases steady-state levels of ubiquitinated p53. (a) Schematic of hHR23A expression constructs. The gray rectangle indicates the XP-C binding domain, and the black rectangle indicates the V5 tag. (b) U2OS cells were cotransfected with pCMV-p53 (.5 mg), pCMV-mdm2 (4 mg) and increasing doses of pcDNA3-V5-hHR23A-FL (2 or 4 mg), Nt (1 or 2 mg) or Ct (2 or 4 mg) for 36 h followed by immunoblotting of cell lysates for p53, MDM2, V5 and GAPDH. Two different exposures are shown for the p53 immunoblot. Arrowhead indicates unmodified p53, and Ub-p53 indicates ubiquitinated p53 species. Asterisks indicate a degradation product of hHR23A-FL and -Nt. (c) U2OS cells were cotransfected with a myc-ubiquitin expression vector (pCW7, 2.5 mg), pCMV-p53 (5 mg), pCMV-mdm2 (4 mg) and pcDNA3-V5-hHR23A-FL (4 mg), Nt (2 mg) or Ct (4 mg). At 36 h after transfection, cell lysates were immunoprecipitated with anti-Myc and immunoblotted for p53. Figure 2a , left panel, and data not shown). hHR23A siRNA also caused decreases in the abundance of exogenous p53 expressed from the CMV promoter in U2OS or H1299 cells (Figure 2b ), but did not effect the expression of b-galactosidase synthesized from a cotransfected pCMV-lacZ plasmid (data not shown) in either cell line, suggesting that the effects of hHR23A knockdown on p53 occur at the posttranscriptional level, and are not cell-type specific.
To further delineate the mechanism by which hHR23A depletion reduced p53 protein levels, the half-life of p53 protein was measured in siRNA-treated U2OS cells by cycloheximide-chase ( Figure 2c ). hHR23A depletion led to a decrease of the p53 halflife from 2.870.2 h in control siRNA-treated cells, to 170.1 h in hHR23A siRNA-treated cells (mean of three independent experiments). Thus, hHR23A depletion resulted in more rapid degradation of p53.
Increased p53 degradation after hHR23A knockdown is proteasome-dependent
To address whether p53 destabilization by hHR23A siRNA was proteasome-dependent, hHR23A-depleted or control cells were treated with proteasome inhibitor. MG-132 treatment stabilized p53 in cells treated with control as well as hHR23A siRNA ( Figure 2d , left panel). The ratio of p53 levels in the presence vs absence of MG-132 was exactly the same in cells with normal or reduced hHR23A levels ( Figure 2d , right panel), although the lower absolute levels of p53 in hHR23A siRNA/MG-132-treated cells vs control siRNA/MG-132-treated cells reflects the lower abundance of p53 in the former case at the start of the MG132 incubation. Data from both overexpression and siRNA knockdown experiments thus suggest that hHR23A regulates p53 turnover in U2OS cells by reducing the rate of its proteasomal degradation.
hHR23A blocks in vitro degradation of p53 by purified 26S proteasome
To probe whether the inhibition of p53 degradation in vivo by hHR23 was direct, hHR23 effects on p53 degradation were studied in a 26S proteasome-dependent in vitro degradation system. p53-ubiquitin conjugates, including a substantial fraction of polyubiquitinated (4100 kDa) species ( Figure 3a) were generated from complexes of p53, MDM2 and p300 Nterminal region synthesized in insect cells (p300 required to maximize polyubiquitination; Grossman et al., 2003) . p53 ubiquitination was dependent on both E1 and E2 ( Figure 3a , lanes 1-2), and incubation of ubiquitinated p53 with mock purified material, or purified hHR23A-FL, Nt or Ct derivatives had no effect on the abundance of native or modified p53 (Figure 3a, lanes 3-7) . Addition of purified 26S proteasome in the presence of proteasome inhibitors also had no effect (Figure 3a , lane 8). Purified 26S proteasome, without inhibitors, caused a striking decrease in the abundance of p53-ubiquitin conjugates, and caused a modest decrease in the amount of native p53 (Figure 3a , lane 9 and b). Ongoing ubiquitination during proteasome incubation, was the likely explanation for the reduction of native, and presumably monoubiquitinated (61-89 kDa; Grossman et al., 2003) p53 species with proteasome incubation.
Consistent with in vivo overexpression data, purified hHR23A-FL and hHR23A-Ct blocked in vitro proteasome degradation of ubiquitinated p53 as capably as the proteasome inhibitor cocktail, whereas mock purified material or hHR23A-Nt had no effect (Figure 3a, b) . hHR23B-FL similarly blocked in vitro degradation p53 (Figure 3b) . Thus, the inhibition of p53 degradation by hHR23 in vivo correlates with the ability of hHR23 to directly inhibit p53 degradation in vitro.
MDM2 excess overcomes hHR23A-mediated inhibition of p53 degradation
To further investigate the hypothesis that hHR23 functions as an inhibitor of p53 degradation, the effects of hHR23A depletion on p53 degradation were studied under conditions of MDM2 excess. MDM2 and p53 proteins were coexpressed in U2OS cells treated with control or hHR23A-specific siRNA (Figure 4a In vitro ubiquitination reactions were performed with p53/MDM2/p300(1-595) complexes in the presence of E1 and E2 (UbcH5a) as indicated. Purified recombinant (His) 6 -hHR23A polypeptides (FL, Nt or Ct) or mock-purified material (Control) were preincubated with ubiquitinated p53 for 1 h at 41C, and 26S proteasome or proteasome inhibitor-treated 26S proteasome were then added to the reaction where indicated. After further incubation, reactions were analysed by p53 immunoblot. The arrowhead and Ub-p53 indicate the migration position of native and ubiquitinated p53 species, respectively. (b) In vitro 26S proteasome-dependent degradation assays were performed as described in panel (a) in the presence of recombinant (His) 6 -hHR23A-FL or hHR23B-FL. The percentage of polyubiquitinated p53 (4100 kDa; (Ub)n) remaining after incubation with active 26S proteasome was determined. Results are the mean of four independent experiments p53 stability regulation by MDM2 and hHR23 C Brignone et al
Treatment of MDM2-expressing cells with hHR23A siRNA, however, did not cause any further decrease in p53 levels (Figure 4a , compare lane 4 to 3), suggesting that in conditions of MDM2 excess, hHR23A depletion has no further effect in accelerating p53 turnover. Thus, MDM2, in excess, can overcome endogenous hHR23A inhibition of p53 degradation, and MDM2 may therefore regulate p53 degradation at multiple steps -as an E3 ubiquitin ligase, and at a post-ubiquitination step, by modulating the degradation inhibition function of hHR23.
hHR23A and MDM2 functionally interact in regulation of p53 degradation Consistent with such an additional role for MDM2 in regulating p53 stability beyond ubiquitin ligase activity, an MDM2 mutant lacking residues 211-240 has been noted to ubiquitinate, but not degrade, p53 in cells (Grossman et al., 1998; Zhu et al., 2001b) . To determine if the inability of MDM2D(211-240) to degrade p53 was due to an inability to abrogate hHR23 inhibition of degradation, cells expressing p53 and this particular MDM2 mutant, or a control mutant, MDM2D(171-200) (Grossman et al., 1998) , were depleted of hHR23A by siRNA knockdown (Figure 4a indicating that the degradation defect of MDM2D (211-240) is related to its inability to counteract hHR23A inhibition of p53 degradation. As the mechanism of the degradation defect of MDM2D(211-240) and its rescue by hHR23A siRNA could depend on indirect cell-specific mechanisms, the ability of MDM2D(211-240) to degrade p53 was studied in vitro. Ubiquitinated p53 was prepared from complexes of MDM2 or MDM2D(211-240) with p53 and p300 N-terminal region polypeptide , and the products of the ubiquitination reaction, including MDM2, were further incubated with chemically inhibited or active purified 26S proteasome (Figure 4b ). Despite the robust ubiquitination of p53 by either wild-type or mutant MDM2, as seen after incubation with inactive proteasome (Figure 4b , lanes 1 and 3), p53 was degraded by the 26S proteasome only when wild-type MDM2, but not mutant MDM2 was present ( Figure 4b, lanes 2 and 4) . Thus, MDM2 residues 211-240, which are required for MDM2 to counteract hHR23A inhibition of p53 degradation in vivo, are dispensable for ubiquitin ligase function and exert a direct biochemical function required for p53 degradation in vitro.
Identification of a novel hHR23A/MDM2 complex
To better understand the mechanism of functional interaction between hHR23 and MDM2, the ability of MDM2 to physically interact with hHR23A was examined in U2OS cells (Figure 5a ). Endogenous hHR23A was detected in an anti-MDM2 IP of U2OS cell lysate (Figure 5a , lane 3) but was not present in a control antibody IP (Figure 5a, lane 7) . Likewise, MDM2 was detected in a reciprocal anti-hHR23A IP of U2OS cell lysate (Figure 5a , lane 5). In addition, the same IPs performed using BJAB B-cell lysate yielded similar results (data not shown), suggesting that MDM2/hHR23A interaction is not cell-type specific. These data suggest that MDM2/hHR23A functional interactions are linked to their physical interaction in cells.
p53 interacts indirectly with hHR23 via MDM2
p53 was also coimmunoprecipitated with hHR23A ( Figure 5a , bottom panel), consistent with either direct binding to hHR23, or an indirect interaction bridged by MDM2. As native p53 was found in the hHR23A IP, the interaction would not be due to the ability of hHR23A UBA domains to interact with polyubiquitinated proteins. Indeed, both native and ubiquitinated p53 purified from insect cells were specifically retained by a (His) 6 -hHR23A resin, and retention of native p53 was strictly dependent on the presence of MDM2 (data not shown). To determine if p53/hHR23A interaction was bridged by MDM2 in vivo, MDM2, p53 and hHR23A were expressed in H1299 cells, which lack p53 and have low endogenous levels of MDM2 (Figure 5b ). p53 was found in an hHR23A IP of transfected cell lysate, but not a control IP, only when exogenous MDM2 was also present (Figure 5b) . Thus, p53 interacts indirectly with hHR23A through MDM2, suggesting that specific, and possibly direct, interaction with MDM2 mediates hHR23 regulation of p53 turnover.
MDM2/hHR23 interaction is direct and correlates with hHR23 interference with p53 degradation
To establish that hHR23A/MDM2 interaction was itself direct and not bridged by other eukaryotic proteins, bacterially derived (His) 6 -hHR23A, (His) 6 -hHR23B, and truncated derivatives, were tested for interaction with bacterial GST-MDM2 (Figure 6a ). Both hHR23A and hHR23B bound GST-MDM2, but not GST, and Nand C-terminal truncations of both hHR23 proteins independently interacted with MDM2 ( Figure 6a , left and right panels). Thus, MDM2 and hHR23 interact directly, and potentially at multiple sites within hHR23.
To determine if hHR23 exhibited multiple interaction sites for MDM2 in vivo, MDM2, p53 and hHR23A or truncated derivatives, were expressed in U2OS cells, and transfected cell lysates were immunoprecipitated with MDM2 antibody (Figure 6b ). hHR23A-FL or hHR23A-Ct, were both found in an MDM2 IP (Figure 6b, lanes 7 and 9) , whereas hHR23A-Nt was not present. The inability of hHR23A-Nt to interact with MDM2 in vivo may reflect occupancy of this portion of hHR23A by the proteasome or other factors which interact with the conserved UbL domain. Moreover, the ability of hHR23A-FL and hHR23A-Ct, but not hHR23A-Nt, to interact with MDM2 in vivo, correlates with their respective abilities to stabilize ubiquitinated forms of p53. (Figure 6c, lanes 4-6) . Surprisingly, sevenfold more hHR23A was noted in anti-MDM2 IPs of lysates from MDM2D(211-240)-transfected vs wild-type MDM2-transfected cells. The 1.3-fold increase in hHR23A abundance in mutant vs wild-type MDM2-expressing cell lysates ( Figure  6c , lanes 2-3) could not completely account for this difference, and equivalent amounts of wild-type and mutant MDM2 were present in each MDM2 IP (Figure 6c, lanes 8-9) . Increased complex formation of MDM2D(211-240) with the degradation-inhibiting hHR23A protein thus correlates with the inability of this MDM2 mutant to degrade p53, and with the rescue of its degradation-defective phenotype by hHR23A knockdown.
Discussion
We have investigated the role of Rad23-family proteins in p53 stability regulation. Removal of hHR23A accelerated p53 degradation, and hHR23 overexpression caused an accumulation of p53-ubiquitin conjugates. hHR23 also blocked in vitro degradation of p53 by the proteasome. hHR23A interference in p53 turnover was counteracted by MDM2, suggesting a role for MDM2 in p53 degradation after ubiquitination. MDM2D(211-240) did not promote p53 degradation, despite normal E3 function, and this degradation-defective phenotype was rescued by hHR23A knockdown. Finally, the functional interaction of hHR23 and MDM2 was reflected in a specific, direct, and physiologic hHR23/MDM2 interaction. Binding of hHR23A or its C-terminal derivative to MDM2 correlated with the ability of either protein to stabilize p53-ubiquitin conjugates. Moreover, the degradation defect of the D211-240 mutant of MDM2 correlated with increased interaction with hHR23A relative to wild-type MDM2 in vivo. hHR23 proteins may establish a 'set-point' for p53 protein levels by tempering the rate of p53 degradation. Our results are consistent with those of a recent report where overexpressed hHR23A stabilized p53-ubiquitin conjugates and blocked in vitro (papillomavirus E6-mediated) degradation of p53 (Glockzin et al., 2003) . However, these investigators saw increases in p53 levels upon microinjection of hHR23 siRNA into primary cells. Our results also differ from those of another previous report where overexpressed hHR23A decreased p53 abundance (Zhu et al., 2001a) . The data of Zhu et al. and Glockzin et al. are indeed consistent with the hypothesis that hHR23A is a proteasome adaptor, although the actual metabolic half-life of p53 was not measured in either report. Indeed, it is quite possible that hHR23A serves a dual role as proteasome adaptor or inhibitor of substrate degradation, depending on cellular context and stoichiometry of all relevant components. Differing effects of hHR23 depletion or overexpression on p53 metabolism among different investigators might thus be due to these same considerations.
hHR23A depletion might have destabilized p53 in our experiments due to preferential loss of an intracellular pool of 'free,' nonproteasome-bound, hHR23A that might block proteasome targeting of substrates through sequestration (Figure 7 ). The effect of overexpressed hHR23 on p53 metabolism could then be explained if exogenous hHR23 preferentially enters the pool of free, nonproteasome-bound, hHR23, where MDM2/p53 complexes would be recruited into inactive nondegradable complexes. hHR23A-Ct lacks the UbL domain required for proteasome interaction, so would also be predicted to sequester MDM2 and p53 in nondegradable complexes. This type of model allows for a dual role of hHR23 and similar proteasome adaptor proteins, and provides one possible explanation for many of the conflicting results regarding Rad23-family function(s) in protein degradation. -3) , or immunoprecipitated with control (c-Myc, lanes 4-6) or MDM2 (SMP14, lanes 7-9) antibodies, followed by V5 and MDM2 immunoblot. Asterisk indicates coimmunoprecipitated hHR23A-FL protein p53 stability regulation by MDM2 and hHR23 C Brignone et al hHR23 and MDM2 appear to counteract each other in regulating p53 turnover. MDM2 in its native conformation was surprisingly required for proper degradation of p53 either in vivo or in vitro. This suggests that MDM2/hHR23 interaction that might aid p53 delivery to the proteasome in a manner promoting its degradation (Figure 7) . The correlation between physical and functional interaction of MDM2 and hHR23A is demonstrated by MDM2D(211-240) which cannot degrade p53, has increased binding with hHR23A in vivo, and is rendered competent to degrade p53 by decreasing intracellular levels of hHR23A. The in vitro degradation defect of this mutant could be due hHR23A found in purified proteasomes (Raasi and Pickart, 2003; unpublished observations) and it would be of interest to determine if p53 degradation activity is restored to this MDM2 mutant, as it is in cells, by depletion of hHR23A from the purified proteasome preparation. It is possible that this mutant MDM2 traps hHR23A and p53 in an inactive complex, and the MDM2 211-240 region might normally provide contacts with the proteasome, or effect conformational change in hHR23, switching its function from an inhibitor of, to adaptor for, substrate degradation.
Taken together, our work suggests that the MDM2/ hHR23 complex is an additional node for p53 stability regulation, and may represent a novel target for therapeutics aimed at stabilizing wild-type p53 in tumors in which its degradation is overactive. Moreover, the interaction of MDM2 and other ubiquitin ligases, such as E6AP, with UbL-UBA proteins (Kumar et al., 1999; Kleijnen et al., 2000) , suggests that ubiquitin ligases may generally assist in the targeting of their substrates to the proteasome.
Materials and methods
Cell culture
U2OS (human osteosarcoma, WT p53), NCI-H1299 (human lung carcinoma, p53 negative) and BJAB (Burkitt lymphoma) cells were maintained in DMEM with 10% FCS (Gemini) at 371C in a 10% CO 2 atmosphere. Sf9 insect cells were maintained in Sf-900 SFM medium (GIBCO) at 281C.
Plasmids and siRNA
pcDNA3-V5-hHR23A derivatives were obtained by PCR amplification of hHR23A fragments, and insertion in pcDNA3.1D/V5-His. TOPO (Invitrogen). pCW7, pCMV-p53 and pCMV-mdm2 (human), D(171-200), and D(211-240) have been described (Ward et al., 1995; Grossman et al., 1998) . pGEX-mdm2 was provided by Dr J Xiao. Plasmids encoding RGS(His) 6 -tagged hHR23 polypeptides were produced by insertion of appropriate restriction fragments into pQE-30, except pQE-hHR23B-FL, which has been described (Reardon et al., 1996) . The target sequences for hHR23A and hHR23B siRNA were AAGAGCCCAUCAGAGGAAUC (hHR23A#1, used for all experiments except where indicated), AACUUCCUCCUGAGUCAGAAC (hHR23A#2) and AAAGUCAGGCUGUGGUUGACC (hHR23B). Control siRNA (control duplex IX) was from Dharmacon.
Transfection, cells lysis and immunoblotting
Cells were transfected using Fugene (Roche). siRNA transfections were performed using Oligofectamine (Invitrogen) and 360 pmol of hHR23A-siRNA/100 mm dish or 600 pmol of hHR23B siRNA. Transfected cells were lysed in lysis buffer (20 mM HEPES pH 7.4, 0.5% Triton X-100, 2 mM MgCl 2 , 10 mM ZnCl 2 , 2 mM NEM, 1 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 2 mM NaF, 2 mM Na orthovanadate, 20 mM MG-132), containing 240 mM NaCl (LB240). Protein concentrations were determined by Bradford assay (Bio-Rad).
For cycloheximide-chase analysis, cells were treated with cycloheximide (40 mg/ml) for various times, washed in PBS containing cycloheximide, and lysed with LB240.
Antibodies used for immunoblot were as follows: p53, DO-1; MDM2, N-20 (Santa Cruz); HSP70, W27 (Santa Cruz); tubulin, B-7, (Santa Cruz); V5 (Invitrogen); GAPDH, 6C5 (Advanced ImmunoChemical) and anti-RGS-His (Qiagen). Anti-hHR23A and hHR23B antibodies were produced by immunization of rabbits with KLH-CGELADISDVEGEV-GAIGEE and KLH-CTSTPASITPASATA, respectively, and were affinity purified against their respective immunizing peptides.
Immunoprecipitations
Cell lysates were prepared with LB170 (0.1%. Triton X-100 for IPs of endogenous proteins), precleared with protein A, incubated with antibody-conjugated beads, and IPs washed with LB140 (0.1% Triton X-100; endogenous proteins) or LB170, followed by immunoblotting. MDM2 (N-20), hHR23A and h-Ras (C-20, Santa Cruz) antibodies were conjugated to CH-Sepharose (Amersham).
In vitro ubiquitination and 26S proteasome-dependent degradation assays p53/MDM2 or MDM2D(211-240)/p300(1-595) complexes were purified from baculovirus-infected Sf9 cells, and ubiquitination reactions were performed as described Wei et al., 2003) . Purified 26S proteasome (1.1 mg) from rabbit muscle (Kisselev et al., 2002) preincubated with 5 mM ubiquitin-aldehyde and proteasome inhibitors (10 mM of each: MG-132, lactacystin, clasto-lactacystin-b-lactone) where indicated was added to ubiquitination reactions along with fresh ATP and further incubation for 5 h at 371C was performed with additional ATP added after the first 2.5 h. Model of hHR23 and MDM2 action in p53 proteasome degradation. hHR23 proteins interact with MDM2, p53, and the proteasome. Proteasome-bound hHR23 might aid in targeting ubiquitinated p53 to the proteasome for degradation when MDM2 is present in the complex. hHR23 not in complex with the proteasome might interfere with p53 degradation by sequestering MDM2/p53 complex from the proteasome p53 stability regulation by MDM2 and hHR23 C Brignone et al
Production of recombinant bacterial proteins and protein interaction assays
Bacteria expressing (His) 6 -hHR23 polypeptides were lysed in PBS containing 240 mM NaCl, 10 mM imidazole, 2 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1% Triton by freezethaw. After centrifugation (30 min at 8000 g), Ni-NTAAgarose (Qiagen) was added to the cleared lysate for 2 h, washed in PBS containing 240 mM NaCl, 20 mM imidazole, 0.5% Triton X-100, and proteins eluted with PBS containing 200 mM imidazole, 0.1% Triton X-100, 15% glycerol. A Ni-NTA control purification was performed from bacteria containing pcDNA3. GST-fusion proteins were obtained by freeze-thaw lysis of IPTG-induced bacteria in 20 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl 2 , 10mM ZnCl 2 , 2mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 2 mM DTT, 5 mg/ml lysozyme, and 1% Triton X-100. GST pulldown assays were performed as described (Grossman et al., 1998) , except that glutathioneSepharose-bound proteins were eluted in 100 mM Tris-HCl pH 8.0, 120 mM NaCl, 20 mM glutathione, 0.1% Triton X-100, 10% glycerol, followed by immunoblotting.
